Clinical development plan: dehydroepiandrosterone (DHEA).
D000368:Aged; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D003687:Dehydroepiandrosterone / Q000494:pharmacology / Q000627:therapeutic use*; D017277:Drug Approval; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000517:prevention & control*; D009374:Neoplasms, Experimental / Q000517:prevention & control; D051381:Rats; D012107:Research Design; D018675:Toxicity Tests
D016588:Anticarcinogenic Agents; D003687:Dehydroepiandrosterone